Karin Beelen

2.4k total citations · 1 hit paper
21 papers, 1.7k citations indexed

About

Karin Beelen is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Karin Beelen has authored 21 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 7 papers in Molecular Biology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Karin Beelen's work include HER2/EGFR in Cancer Research (9 papers), Advanced Breast Cancer Therapies (7 papers) and PI3K/AKT/mTOR signaling in cancer (7 papers). Karin Beelen is often cited by papers focused on HER2/EGFR in Cancer Research (9 papers), Advanced Breast Cancer Therapies (7 papers) and PI3K/AKT/mTOR signaling in cancer (7 papers). Karin Beelen collaborates with scholars based in Netherlands, Belgium and United Kingdom. Karin Beelen's co-authors include Sabine C. Linn, Hugo M. Horlings, Michael Hauptmann, René Bernards, E. Marielle Hijmans, Mandy Madiredjo, Bryan T. Hennessy, Marc J. van de Vijver, Katherine Stemke‐Hale and Ana M. González-Angulo and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Cell and British Journal of Cancer.

In The Last Decade

Karin Beelen

20 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer

2007 1.2k citations Katrien Berns, Hugo M. Horlings et al. Cancer Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Karin Beelen Netherlands	12	1.1k	942	438	410	403	21	1.7k
Brent N. Rexer United States	21	910 0.8×	1.0k 1.1×	407 0.9×	334 0.8×	332 0.8×	38	1.8k
Ariella B. Hanker United States	15	759 0.7×	942 1.0×	445 1.0×	211 0.5×	453 1.1×	41	1.6k
Neil A. O’Brien United States	23	1.0k 0.9×	821 0.9×	455 1.0×	375 0.9×	265 0.7×	55	1.6k
Joan T. Garrett United States	19	1.1k 1.0×	1.2k 1.2×	392 0.9×	599 1.5×	229 0.6×	30	2.0k
Claudia Aura Spain	17	1.3k 1.1×	868 0.9×	428 1.0×	341 0.8×	618 1.5×	35	2.1k
María G. Kuba United States	14	773 0.7×	897 1.0×	445 1.0×	165 0.4×	370 0.9×	20	1.5k
Yasir H. Ibrahim United States	12	828 0.8×	1.1k 1.1×	305 0.7×	163 0.4×	249 0.6×	22	1.6k
Ilenia Migliaccio Italy	23	1.2k 1.1×	828 0.9×	828 1.9×	183 0.4×	583 1.4×	64	2.1k
Rosa Caputo Italy	20	1.3k 1.2×	1.0k 1.1×	906 2.1×	218 0.5×	355 0.9×	21	2.3k
Iwan Beuvink Switzerland	11	840 0.8×	1.1k 1.2×	204 0.5×	272 0.7×	304 0.8×	13	1.7k

Countries citing papers authored by Karin Beelen

Since Specialization

Citations

This map shows the geographic impact of Karin Beelen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karin Beelen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karin Beelen more than expected).

Fields of papers citing papers by Karin Beelen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karin Beelen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karin Beelen. The network helps show where Karin Beelen may publish in the future.

Co-authorship network of co-authors of Karin Beelen

This figure shows the co-authorship network connecting the top 25 collaborators of Karin Beelen. A scholar is included among the top collaborators of Karin Beelen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karin Beelen. Karin Beelen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mathijssen, Ron H.J., Maaike de Boer, Joan B. Heijns, et al.. (2025). Trifluridine-tipiracil in previously treated patients with oestrogen receptor-positive, HER2-negative metastatic breast cancer (BOOG 2019-01 TIBET trial): a single-arm, multicentre, phase 2 trial. EClinicalMedicine. 80. 103065–103065. 1 indexed citations

Sonke, Gabe S., Vincent van der Noort, Astrid C P Swinkels, et al.. (2023). Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC).. Journal of Clinical Oncology. 41(17_suppl). LBA1000–LBA1000. 55 indexed citations

Oliveira, Mafalda, Richard D. Baird, Susana Muñoz, et al.. (2021). LBA18 POSEIDON randomized phase II trial: Tamoxifen (TAM) + taselisib or placebo (PLA) in patients (pts) with hormone receptor positive (HR+)/HER2- metastatic breast cancer (MBC). Annals of Oncology. 32. S1291–S1292. 3 indexed citations

Beelen, Karin, et al.. (2021). [Confusion and abdominal pain after COVID-19 vaccination].. Nederlandsch tijdschrift voor geneeskunde/Nederlands tijdschrift voor geneeskunde/NTvG-databank. 165. 20. 1 indexed citations

Opdam, Mark, Vincent van der Noort, Joyce Sanders, et al.. (2020). PI3K pathway protein analyses in metastatic breast cancer patients receiving standard everolimus and exemestane. Journal of Cancer Research and Clinical Oncology. 146(11). 3013–3023. 6 indexed citations

Sobral‐Leite, Marcelo, Mark Opdam, Karin Beelen, et al.. (2019). Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes. Breast Cancer Research. 21(1). 90–90. 82 indexed citations

Steenbruggen, Tessa G., Carolien H. Smorenburg, Hánah N. Rier, et al.. (2019). Radiological complete remission in HER2-positive metastatic breast cancer patients: what to do with trastuzumab?. Breast Cancer Research and Treatment. 178(3). 597–605. 15 indexed citations

Beelen, Karin, Mark Opdam, Tesa Severson, et al.. (2018). Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot. BMC Cancer. 18(1). 761–761. 6 indexed citations

Beelen, Karin, Mark Opdam, Joyce Sanders, et al.. (2018). Hierarchical clustering of activated proteins in the PI3K and MAPK pathways in ER-positive, HER2-negative breast cancer with potential therapeutic consequences. British Journal of Cancer. 119(7). 832–839. 18 indexed citations

10.

Loef, M., et al.. (2017). [Relapse of chronic inflammatory demyelinating polyneuropathy following treatment with zoledronic acid].. PubMed. 161. D1747–D1747.

11.

Baird, Richard D., Annelot van Rossum, Mafalda Oliveira, et al.. (2016). POSEIDON trial phase 1b results: Safety and preliminary efficacy of the isoform selective PI3K inhibitor taselisib (GDC-0032) combined with tamoxifen in hormone receptor (HR) positive, HER2-negative metastatic breast cancer (MBC) patients (pts) - including response monitoring by plasma circulating tumor (ct) DNA.. Journal of Clinical Oncology. 34(15_suppl). 2520–2520. 7 indexed citations

12.

Alexi, Xanthippi, Karin Beelen, Marleen Kok, et al.. (2015). Protein Kinase A-induced tamoxifen resistance is mediated by anchoring protein AKAP13. BMC Cancer. 15(1). 588–588. 21 indexed citations

13.

Koornstra, Rutger H.T., Karin Beelen, Andrew Vincent, et al.. (2015). St. Gallen endocrine response classes predict recurrence rates over time. The Breast. 24(6). 705–712. 4 indexed citations

14.

Beelen, Karin, Mark Opdam, Jelle Wesseling, et al.. (2014). PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy. International Journal of Cancer. 135(5). 1257–1263. 26 indexed citations

15.

Beelen, Karin, Mark Opdam, Tesa Severson, et al.. (2014). PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients. Breast Cancer Research. 16(1). R13–R13. 46 indexed citations

16.

Beelen, Karin, Mark Opdam, Tesa Severson, et al.. (2014). Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment. Breast Cancer Research. 16(1). R6–R6. 36 indexed citations

17.

Beelen, Karin, Mark Opdam, Tesa Severson, et al.. (2013). CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment. Breast Cancer Research and Treatment. 139(3). 649–655. 21 indexed citations

18.

Droog, Marjolein, Karin Beelen, Sabine C. Linn, & Wilbert Zwart. (2013). Tamoxifen resistance: From bench to bedside. European Journal of Pharmacology. 717(1-3). 47–57. 84 indexed citations

19.

Beelen, Karin, Wilbert Zwart, & Sabine C. Linn. (2012). Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?. Nature Reviews Clinical Oncology. 9(9). 529–541. 59 indexed citations

20.

Berns, Katrien, Hugo M. Horlings, Bryan T. Hennessy, et al.. (2007). A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer. Cancer Cell. 12(4). 395–402. 1236 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact